--Meta Signs Deal Worth Over $100 Million to Use Black Forest Labs' Technology, Bloomberg Reports-March 2024-www.financetom.com

--Meta Signs Deal Worth Over $100 Million to Use Black Forest Labs' Technology, Bloomberg Reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Meta Signs Deal Worth Over $100 Million to Use Black Forest Labs' Technology, Bloomberg Reports

Sep 9, 2025 12:12 PM

02:53 PM EDT, 09/09/2025 (MT Newswires) --

Price: 764.11, Change: +11.81, Percent Change: +1.57

Previous page： Peltz's Trian, General Catalyst raise offer for Janus Henderson Next page： BRIEF-1Gt Portfolio Investment Huel To Be Acquired By Danone

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Peltz's Trian, General Catalyst raise offer for Janus Henderson

Mar 24, 2026

March 24 (Reuters) - Janus Henderson ( JHG ) said on Tuesday that Trian and General Catalyst have raised their bid to acquire the asset manager to $52 per share. The new offer, which represents a 25% premium to Janus' unaffected stock price and is $3 per share higher than the previous bid, comes amid a high-stakes battle with Victory...

BRIEF-1Gt Portfolio Investment Huel To Be Acquired By Danone

Mar 24, 2026

Morgan Stanley ( MS ): * 1GT PORTFOLIO INVESTMENT HUEL TO BE ACQUIRED BY DANONE Source text: Further company coverage: ...

Core & Main Fiscal Q4 Adjusted Earnings Increase, Net Sales Decrease; Fiscal 2026 Sales Guidance Initiated

Mar 24, 2026

08:11 AM EDT, 03/24/2026 (MT Newswires) -- Core & Main ( CNM ) reported fiscal Q4 adjusted earnings Tuesday of $0.52 per diluted share, up from $0.51 a year earlier. Analysts polled by FactSet expected $0.48. Net sales for the fiscal quarter ended Feb. 1 were $1.58 billion, down from $1.70 billion a year earlier. Analysts surveyed by FactSet expected...

Karyopharm's drug reduces spleen size in rare blood cancer study

Mar 24, 2026

March 24 (Reuters) - Karyopharm Therapeutics ( KPTI ) said on Tuesday its therapy for patients with a rare blood cancer showed a reduction in spleen size in a late-stage trial, meeting one of the two main goals of the study. Shares of the company were up nearly 14% in premarket trade. In the 353-patient trial, half of those given...